The company believes it can overcome its challenges, and highlighted strong continued interest from pharma despite a disappointing end to its Merck deal.
In Science this week: gut microbes affect how cancer patients respond to immunotherapy, and more.
A pair of papers point to potential gut microbial contributions to checkpoint blockade immunotherapy response in individuals with lung, kidney, or skin cancer.
The partners will test samples from an NSABP biobank on Nanostring's platform and with standard IHC to look for newer biomarkers of cancer immune evasion.
Alterations affecting the antigen presentation-related gene B2M appeared to be over-represented in melanomas with checkpoint blockade non-response or resistance.
The researchers plan to add the MSI detection capabilities to an NGS panel and will use the information to guide cancer patients to precision medicine trials.
Gizmodo reports that some cancer patients are turning to DIY immunotherapies.
The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.
The results of the study could have implications for liquid biopsy developers that aim to pick out patients more likely to respond to immunotherapies.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.
The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.
New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.
In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.